Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both the CSF-1 and the TNFα gene sets were enriched in the colonic mucosal transcriptomes of Crohn's disease and in mouse colitis, and expression of both gene sets was highest in patients who did not respond to anti-TNFα therapy.
|
31710624 |
2019 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
NOD2/CARD15 was associated with ileal involvement, while presence of TNF-863A was inversely associated with ileal disease (OR = 0.42, p= 0.008) and positively associated with isolated colitis (OR = 2.16, p= 0.008, OR = 2.12, p= 0.03 corrected) and familial disease (p= 0.004).
|
15667501 |
2005 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a prospective, multicenter, one-year study biologic naïve patients aged 25-65 years, with corticosteroid-dependent or refractory colitis received combination treatment with anti-TNFα and azathioprine for 6 months followed by anti-TNFα monotherapy.
|
27866814 |
2017 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggested that SGK1 may protect IECs in colitis from tumor necrosis factor-α-induced apoptosis partly by triggering MEK/ERK activation.
|
26034353 |
2015 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intrarectal calprotectin protected significantly against colitis, as shown by lower levels of macroscopic and microscopic damage, colonic myeloperoxidase activity and decreased expression of TNFα and toll-like receptor 4.
|
30007036 |
2018 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, probiotic VSL#3 inhibits the expression of NF-κB and TNF-α in rats with colitis through TLR4-NF-κB signal pathway, so it is expected to be a first choice drug for the treatment of colitis.
|
31497551 |
2019 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MIR301A-knockout mice were resistant to the development of colitis following administration of DSS; their colon tissues expressed lower levels of interleukin 1β (IL1β), IL6, IL8, and tumor necrosis factor than colons of control mice.
|
28193514 |
2017 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutralization of TNF-α in dextran sulfate sodium (DSS)-induced colitis mice demonstrates improved the outcomes, and the therapeutic effect of the TNF-α neutralizing mAb is mediated in part by the preservation of DRA expression.
|
29330471 |
2018 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo: KLD significantly improves body weight, clinical score, histological score and large intestine length of mice with DSS-induced colitis and reduces TNF-α, IL-1β and IL-6 mRNA levels, while increases IL-10 mRNA and VDR levels.
|
29633636 |
2018 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inulins inhibited the development of dextran sulfate sodium-induced colitis and colon cancer in mice; these fructans reduced the concentration of tumor necrosis factor alpha and prevented the formation of intestinal polyps, villous atrophy, and lymphoid hyperplasia.
|
28293641 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the incubation of MSCs with TNF-α and IFN-γ aggravates colitis, where high levels of pro-inflammatory factors, such as interleukin (IL)-17, IL-8, IL-12, IL-1β, transforming growth factor (TGF)-β, TNF-α and IFN-γ, were secreted.
|
31632588 |
2019 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of LMWH-NP at 500 IU/kg has markedly improved the clinical activity as compared to LMWH while similarly pathophysiological indicators revealed increased therapeutic outcome in presence of NP compared to LMWH alone: Myeloperoxidase (Colitis control: 10 480 ± 5335, LMWH-PEMT-A NP: 1507 ± 2165, LMWH-PEMT-B NP: 382 ± 143, LMWH: 8549 ± 5021 units/g) and tumor necrosis factor: (Colitis control: 1636 ± 544, LMWH-PEMT-A NP: 511 ± 506, LMWH-PEMT-B NP: 435 ± 473, LMWH: 1110 ± 309 pg/g).
|
28509629 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mechanically, reduced NF-κВ DNA phosphorylation activity and downregulated TNF-α, IL-1β, IL-6, IL-17 expressions and myeloperoxidase (MPO) activity were associated with improvement in colitis observed in APS-treated mice.
|
28188801 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNBS significantly elevated myeloperoxidase (MPO) expression, macroscopic scores, and colon shortening.Oral <i>L. sakei</i> S1 administration resulted in reduction of TNBS-induced loss in body weight, colon shortening, MPO activity, expression of cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B (NF-κB).<i>L. sakei</i> S1 inhibited the expression of inflammatory cytokines IL-1β, IL-6 and TNF-α, induced by TNBS, but enhanced IL-10 expression.<i>L. sakei</i> S1 showed resistance to artificial digestive juices and adherence to intestinal epithelial Caco-2 cells.Thus, <i>L. sakei</i> S1 may inhibit the NF-κB pathway and be used as functional food to treat colitis.
|
31635441 |
2020 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cux1 expression increased in cultured intestinal epithelial cells stimulated with tumor necrosis factor alpha (TNFα), in the mouse intestinal epithelium during experimental colitis and in human IBD patient samples.
|
20848487 |
2010 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However a role of TNF-α in the regulation of NHE-2 is discounted in the present model of colitis.
|
28493993 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that ginsenoside Rg1 markedly reduces proinflammatory cytokines release upon DSS stimulation of mouse dendritic cells, that ginsenoside Rg1 suppresses IL-1β (Interleukin 1 beta) and TNF-α (Tumor necrosis factor alpha) release via up-regulation of NLRP12 (NACHT, LRR and PYD domains-containing protein 12) expression, and that ginsenoside Rg1 significantly decreases the inflammatory response to DSS-induced mouse colitis, as evidenced by increased body weight, reduced colonic damage scores and disease activity index (DAI), and lowered proinflammatory cytokines levels.
|
28605639 |
2017 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The loss of NLRX1 results in increased disease severity, populations of Th1 and Th17 cells, and inflammatory markers (IFN-γ, TNF-α, and IL-17) in mice with dextran sodium sulfate-induced colitis.
|
28159898 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Induction of colitis and JGT treatment changed compositions of gut microbiota and inflammatory cytokine levels (TNF-<i>α</i> and IL-6).
|
30800169 |
2019 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim was to investigate the expression of CDX2 and MEP1A in colitis; to assess if they are regulated by tumor necrosis factor-α (TNF-α), and finally to reveal if CDX2 is involved in a TNF-α-induced down-regulation of MEP1A.
|
22326557 |
2012 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Colitis was induced in mice by transfer of CD4+CD45RB<sup>hi</sup> to FcγR<sup>-/-</sup>Rag1<sup>-/-</sup> or Rag1<sup>-/-</sup> littermates; mice were given different antibodies against TNF or isotype (control) antibodies and disease activity index scores were determined.
|
28756234 |
2017 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
DAI evaluation, colon length, colon tissue morphology, histologic damage scores and relative protein concentrations (MPO, TNF-α and IL-1β) demonstrated that the Alg/Chi/IL-1Ra microcapsules alleviated DSS-induced colitis in mice.
|
30779979 |
2019 |
Colitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of the tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) system reduces intestinal cell death and disease development in several models of colitis.
|
26012567 |
2015 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In mice with colitis, ultrasound delivery of unencapsulated siRNA against Tnf mRNA reduced protein levels of TNF in colon tissues, compared with mice with colitis given siRNA against Tnf mRNA without ultrasound (P ≤ .014), and reduced features of inflammation (P ≤ 4.1 × 10<sup>-5</sup>).
|
28088460 |
2017 |
Colitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression and activation of Smad1, a positive regulator of hepcidin transcription, were assessed during colitis and following administration or neutralization of TNFα.
|
22675442 |
2012 |